1. patient is in need of acute hospitalization per clinician assessment. 2. pregnant or nursing women. 3. unwillingness or inability to comply with procedures required in this protocol. 4. patient requires supplemental oxygen. 5. patient is currently receiving, has received within the past 7 days or is expected to receive during the course of the study remdesivir, or other specific antiviral or anticytokine therapy for covid-19, other than therapeutic monoclonal antibodies allowed or approved in the region in which the patient lives, or systemic corticosteroid equivalent to ≥20 mg daily prednisone/3 mg dexamethasone daily. 6. patient is currently receiving or has received within 30 days prior to screening any other investigational agent for any indication, including approved agents given for investigational indications (e.g., anti-cytokine treatments). 7. patient is currently taking or is expected to start taking warfarin, apixaban (eliquis), or rivaroxaban (xarelto). patients may be taking or start on study dabigatran (pradaxa), standard or low molecular weight heparin.

1. patient is in need of acute hospitalization per clinician assessment. 2. pregnant or nursing women. 3. unwillingness or inability to comply with procedures required in this protocol. 4. patient requires supplemental oxygen. 5. patient is currently receiving, has received within the past 7 days or is expected to receive during the course of the study remdesivir, or other specific antiviral or anticytokine therapy for covid-19, other than therapeutic monoclonal antibodies allowed or approved in the region in which the patient lives, or systemic corticosteroid equivalent to ≥20 mg daily prednisone/3 mg dexamethasone daily. 6. patient is currently receiving or has received within 30 days prior to screening any other investigational agent for any indication, including approved agents given for investigational indications (e.g., anti-cytokine treatments). 7. patient is currently taking or is expected to start taking warfarin, apixaban (eliquis), or rivaroxaban (xarelto). patients may be taking or start on study dabigatran (pradaxa), standard or low molecular weight heparin.

patient is in need of acute hospitalization per clinician assessment. pregnant or nursing women. unwillingness or inability to comply with procedures required in this protocol. patient requires supplemental oxygen. patient is currently receiving, has received within the past 7 days or is expected to receive during the course of the study remdesivir, or other specific antiviral or anticytokine therapy for covid-19, other than therapeutic monoclonal antibodies allowed or approved in the region in which the patient lives, or systemic corticosteroid equivalent to ≥20 mg daily prednisone/3 mg dexamethasone daily. patient is currently receiving or has received within 30 days prior to screening any other investigational agent for any indication, including approved agents given for investigational indications (e.g., anti-cytokine treatments). patient is currently taking or is expected to start taking warfarin, apixaban (eliquis), or rivaroxaban (xarelto). patients may be taking or start on study dabigatran (pradaxa), standard or low molecular weight heparin.

patient is in need of acute hospitalization per clinician assessment. pregnant or nursing women. unwillingness or inability to comply with procedures required in this protocol. patient requires supplemental oxygen. patient is currently receiving, has received within the past 7 days or is expected to receive during the course of the study remdesivir, or other specific antiviral or anticytokine therapy for covid-19, other than therapeutic monoclonal antibodies allowed or approved in the region in which the patient lives, or systemic corticosteroid equivalent to ≥20 mg daily prednisone/3 mg dexamethasone daily. patient is currently receiving or has received within 30 days prior to screening any other investigational agent for any indication, including approved agents given for investigational indications (e.g., anti-cytokine treatments). patient is currently taking or is expected to start taking warfarin, apixaban (eliquis), or rivaroxaban (xarelto). patients may be taking or start on study dabigatran (pradaxa), standard or low molecular weight heparin.

1. patient is in need of acute hospitalization per clinician assessment. 2. pregnant or nursing women. 3. unwillingness or inability to comply with procedures required in this protocol. 4. patient requires supplemental oxygen. 5. patient is currently receiving, has received within the past 7 days or is expected to receive during the course of the study remdesivir, or other specific antiviral or anticytokine therapy for covid-19, other than therapeutic monoclonal antibodies allowed or approved in the region in which the patient lives, or systemic corticosteroid equivalent to ≥20 mg daily prednisone/3 mg dexamethasone daily. 6. patient is currently receiving or has received within 30 days prior to screening any other investigational agent for any indication, including approved agents given for investigational indications (e.g., anti-cytokine treatments). 7. patient is currently taking or is expected to start taking warfarin, apixaban (eliquis), or rivaroxaban (xarelto). patients may be taking or start on study dabigatran (pradaxa), standard or low molecular weight heparin.

1. patient is in need of acute hospitalization per clinician assessment. 2. pregnant or nursing women. 3. unwillingness or inability to comply with procedures required in this protocol. 4. patient requires supplemental oxygen. 5. patient is currently receiving, has received within the past 7 days or is expected to receive during the course of the study remdesivir, or other specific antiviral or anticytokine therapy for covid-19, other than therapeutic monoclonal antibodies allowed or approved in the region in which the patient lives, or systemic corticosteroid equivalent to ≥20 mg daily prednisone/3 mg dexamethasone daily. 6. patient is currently receiving or has received within 30 days prior to screening any other investigational agent for any indication, including approved agents given for investigational indications (e.g., anti-cytokine treatments). 7. patient is currently taking or is expected to start taking warfarin, apixaban (eliquis), or rivaroxaban (xarelto). patients may be taking or start on study dabigatran (pradaxa), standard or low molecular weight heparin.

1. patient is in need of acute hospitalization per clinician assessment. 2. pregnant or nursing women. 3. unwillingness or inability to comply with procedures required in this protocol. 4. patient requires supplemental oxygen. 5. patient is currently receiving, has received within the past 7 days or is expected to receive during the course of the study remdesivir, chloroquine, hydroxychloroquine, azithromycin or other specific antiviral therapy for covid-19 or systemic corticosteroid equivalent to ≥20 mg daily prednisone/3 mg dexamethasone daily. 6. patient is currently receiving or has received within 30 days prior to screening any other investigational agent for any indication, including approved agents given for investigational indications (e.g., anti-cytokine treatments). 7. patient is currently taking or is expected to start taking warfarin, apixaban (eliquis), or rivaroxaban (xarelto). patients may be taking or start on study dabigatran (pradaxa), standard or low molecular weight heparin.

1. patient is in need of acute hospitalization per clinician assessment. 2. pregnant or nursing women. 3. unwillingness or inability to comply with procedures required in this protocol. 4. patient requires supplemental oxygen. 5. patient is currently receiving, has received within the past 7 days or is expected to receive during the course of the study remdesivir, chloroquine, hydroxychloroquine, azithromycin or other specific antiviral therapy for covid-19 or systemic corticosteroid equivalent to ≥20 mg daily prednisone/3 mg dexamethasone daily. 6. patient is currently receiving or has received within 30 days prior to screening any other investigational agent for any indication, including approved agents given for investigational indications (e.g., anti-cytokine treatments). 7. patient is currently taking or is expected to start taking warfarin, apixaban (eliquis), or rivaroxaban (xarelto). patients may be taking or start on study dabigatran (pradaxa), standard or low molecular weight heparin.